Optimization of Lung Surfactant Coating of siRNA Polyplexes for Pulmonary Delivery

被引:7
|
作者
Baldassi, Domizia [1 ]
Ngo, Thi My Hanh [1 ]
Merkel, Olivia M. [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, Dept Pharm Pharmaceut Technol & Biopharmaceut, Butenandtstr 5, D-81377 Munich, Germany
基金
欧洲研究理事会;
关键词
air-liquid interface; polyplexes; pulmonary delivery; pulmonary surfactant; siRNA delivery; IN-VITRO; DRUG; MODELS; MUCUS; VIVO;
D O I
10.1007/s11095-022-03443-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose The aim of this study was to understand how coating with a pulmonary surfactant, namely Alveofact, affects the physicochemical parameters as well as in vitro behavior of polyethylenimine (PEI) polyplexes for pulmonary siRNA delivery. Methods Alveofact-coated polyplexes were prepared at different Alveofact:PEI coating ratios and analyzed in terms of size, PDI and zeta potential as well as morphology by transmission electron microscopy. The biological behavior was evaluated in a lung epithelial cell line regarding cell viability, cellular uptake via flow cytometry and gene downregulation by qRT-PCR. Furthermore, a 3D ALI culture model was established to test the mucus diffusion and cellular uptake by confocal microscopy as well as gene silencing activity by qRT-PCR. Results After optimizing the coating process by testing different Alveofact:PEI coating ratios, a formulation with suitable parameters for lung delivery was obtained. In lung epithelial cells, Alveofact-coated polyplexes were well tolerated and internalized. Furthermore, the coating improved the siRNA-mediated gene silencing efficiency. Alveofact-coated polyplexes were then tested on a 3D air-liquid interface (ALI) culture model that, by expressing tight junctions and secreting mucus, resembles important traits of the lung epithelium. Here, we identified the optimal Alveofact:PEI coating ratio to achieve diffusion through the mucus layer while retaining gene silencing activity. Interestingly, the latter underlined the importance of establishing appropriate in vitro models to achieve more consistent results that better predict the in vivo activity. Conclusion The addition of a coating with pulmonary surfactant to polymeric cationic polyplexes represents a valuable formulation strategy to improve local delivery of siRNA to the lungs.
引用
收藏
页码:77 / 91
页数:15
相关论文
共 50 条
  • [21] Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA
    Guagliardo, Roberta
    Merckx, Pieterjan
    Zamborlin, Agata
    De Backer, Lynn
    Echaide, Mercedes
    Perez-Gil, Jesus
    De Smedt, Stefaan C.
    Raemdonck, Koen
    PHARMACEUTICS, 2019, 11 (09)
  • [22] Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery
    Zimmermann, Christoph M.
    Baldassi, Domizia
    Chan, Karen
    Adams, Nathan B. P.
    Neumann, Alina
    Porras-Gonzalez, Diana Leidy
    Wei, Xin
    Kneidinger, Nikolaus
    Stoleriu, Mircea Gabriel
    Burgstaller, Gerald
    Witzigmann, Dominik
    Luciani, Paola
    Merkel, Olivia M.
    JOURNAL OF CONTROLLED RELEASE, 2022, 351 : 137 - 150
  • [23] Pulmonary Delivery of Butyrylcholinesterase as a Model Protein to the Lung
    Rahhal, Tojan B.
    Fromen, Catherine A.
    Wilson, Erin M.
    Kai, Marc P.
    Shen, Tammy W.
    Luft, J. Christopher
    DeSimone, Joseph M.
    MOLECULAR PHARMACEUTICS, 2016, 13 (05) : 1626 - 1635
  • [24] Factors influencing polycation/siRNA colloidal stability toward aerosol lung delivery
    Steele, Terry W. J.
    Zhao, Xiaobin
    Tarcha, Peter
    Kissel, Thomas
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 80 (01) : 14 - 24
  • [25] RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells
    Bo Lou
    Kate Connor
    Kieron Sweeney
    Ian S. Miller
    Alice O’Farrell
    Eduardo Ruiz-Hernandez
    David M. Murray
    Garry P. Duffy
    Alan Wolfe
    Enrico Mastrobattista
    Annette T. Byrne
    Wim E. Hennink
    Drug Delivery and Translational Research, 2019, 9 : 679 - 693
  • [26] RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells
    Lou, Bo
    Connor, Kate
    Sweeney, Kieron
    Miller, Ian S.
    O'Farrell, Alice
    Ruiz-Hernandez, Eduardo
    Murray, David M.
    Duffy, Garry P.
    Wolfe, Alan
    Mastrobattista, Enrico
    Byrne, Annette T.
    Hennink, Wim E.
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2019, 9 (03) : 679 - 693
  • [27] Small nanosized poly(vinyl benzyl trimethylammonium chloride) based polyplexes for siRNA delivery
    Lou, Bo
    Beztsinna, Nataliia
    Mountrichas, Grigoris
    van den Dikkenberg, Joep B.
    Pispas, Stergios
    Hennink, Wim E.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 525 (02) : 388 - 396
  • [28] The advantages of pulmonary delivery of therapeutic siRNA
    Feldmann, Daniel P.
    Merkel, Olivia M.
    THERAPEUTIC DELIVERY, 2015, 6 (04) : 407 - 409
  • [29] Nanoscale particles for lung delivery of siRNA
    Nascimento, T. L.
    Hillaireau, H.
    Fattal, E.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2012, 22 (01) : 99 - 108
  • [30] Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome
    Zoulikha, Makhloufi
    Xiao, Qingqing
    Boafo, George Frimpong
    Sallam, Marwa A.
    Chen, Zhongjian
    He, Wei
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (02) : 600 - 620